The Dave Chang Show
Destigmatizing Psychedelics With Beau Kilmer
Mar 27, 2025
Beau Kilmer, co-director of the RAND Drug Policy Research Center and an expert on drug policy, joins the conversation to discuss the future of psychedelics in the U.S. He delves into how societal attitudes toward substances like psilocybin and cannabis have shifted over time, often shaped by misinformation and cultural stigmas. Kilmer highlights the emerging therapeutic applications of psychedelics in mental health, reflecting on the challenges of regulatory hurdles and the importance of scientific research in changing perceptions.
01:15:39
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Psychedelics are gaining acceptance similar to cannabis, with psilocybin showing potential benefits for conditions like depression and PTSD.
- The stigmatization of psychedelics mirrors past misconceptions about food ingredients, highlighting the need for shifts in public perception.
Deep dives
Expert Insight on Psychedelics
Psychedelics, particularly psilocybin found in certain mushrooms, are gaining attention for their potential medical benefits. Experts suggest that psilocybin could be beneficial in treating conditions like depression and PTSD, similar to how marijuana has evolved from a prohibited substance to an accepted treatment in many states. The progression towards acceptance often hinges on scientific research and public perception, and there's a growing body of clinical studies indicating positive outcomes for mental health treatment. This reevaluation of psychedelics parallels the journey of cannabis, where initially vilified substances are now being reviewed for their therapeutic potential.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
